INmune Bio Inc (NASDAQ: INMB) kicked off on Monday, up 19.13% from the previous trading day, before settling in for the closing price of $5.49. Over the past 52 weeks, INMB has traded in a range of $4.32-$14.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 401.55%. While this was happening, its average annual earnings per share was recorded -37.44%. With a float of $15.76 million, this company’s outstanding shares have now reached $22.17 million.
Let’s determine the extent of company efficiency that accounts for 17 employees. In terms of profitability, gross margin is 100.0%, operating margin of -98921.43%, and the pretax margin is -98266.67%.
INmune Bio Inc (INMB) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of INmune Bio Inc is 28.90%, while institutional ownership is 26.83%. The most recent insider transaction that took place on Sep 30 ’24, was worth 52,868. In this transaction Chief Financial Officer of this company bought 10,000 shares at a rate of $5.29, taking the stock ownership to the 1,285,869 shares. Before that another transaction happened on Sep 12 ’24, when Company’s President and CEO bought 15,380 for $6.38, making the entire transaction worth $98,048. This insider now owns 1,554,106 shares in total.
INmune Bio Inc (INMB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.44% per share during the next fiscal year.
INmune Bio Inc (NASDAQ: INMB) Trading Performance Indicators
Take a look at INmune Bio Inc’s (INMB) current performance indicators. Last quarter, stock had a quick ratio of 2.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3625.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -2.04 in one year’s time.
Technical Analysis of INmune Bio Inc (INMB)
Looking closely at INmune Bio Inc (NASDAQ: INMB), its last 5-days average volume was 0.54 million, which is a jump from its year-to-date volume of 0.48 million. As of the previous 9 days, the stock’s Stochastic %D was 66.08%. Additionally, its Average True Range was 0.47.
During the past 100 days, INmune Bio Inc’s (INMB) raw stochastic average was set at 79.00%, which indicates a significant decrease from 88.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.72% in the past 14 days, which was higher than the 74.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.22, while its 200-day Moving Average is $7.36. However, in the short run, INmune Bio Inc’s stock first resistance to watch stands at $7.00. Second resistance stands at $7.46. The third major resistance level sits at $8.08. If the price goes on to break the first support level at $5.92, it is likely to go to the next support level at $5.30. Now, if the price goes above the second support level, the third support stands at $4.84.
INmune Bio Inc (NASDAQ: INMB) Key Stats
The company with the Market Capitalisation of 145.01 million has total of 22,172K Shares Outstanding. Its annual sales at the moment are 160 K in contrast with the sum of -30,010 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -9,750 K.